UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 10, 2014

ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

DELAWARE	**001-35813**	**98-0376008**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel	**91390**
(Address of Principal Executive Offices)	(Zip Code)

+972-2-566-0001
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. REGULATION FD DISCLOSURE.

Oramed Pharmaceuticals Inc., or Oramed, has posted an updated corporate presentation to its website. A copy of the presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

ITEM 8.01. OTHER EVENTS.

In addition, on February 10, 2014, Oramed announced that it had submitted a protocol to the U.S. Food and Drug Administration to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.2 and incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Corporate Presentation
99.2 Press release issued by Oramed on February 10, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORAMED PHARMACEUTICALS INC.

By: /s/ Nadav Kidron
Name: Nadav Kidron
Title: President and CEO

February 12, 2014

Exhibit 99.1


oramed
Pharmaceuticals Inc
Breakthrough Technology for a Brighter Future
February 2014

Safe Harbor

Certain statements contained in this material are forward-looking statements. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities, and others, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.

Oramed Overview

Proprietary Protein Oral Delivery (POD™) platform technology

For the oral delivery of drugs that are currently only available via injection

Product Pipeline

- Oral Insulin (ORMD-0801)
  - Type 2 diabetes
  - Type 1 diabetes
- Oral GLP-1 Analog (ORMD-0901)
- Combination Therapy (ORMD 0801 + 0901)

Proof of Concept established in preclinical and clinical trials

Publicly traded - NASDAQCM:ORMP

Founded in 2006 by its scientific inventors after more than two decades of research

Agenda Overview

Oral Administration	The Challenge The Oramed Solution
Diabetes	Statistics and Market
Oramed Pipeline	Oral Insulin Oral GLP-1 Analog
Corporate Overview	Management Team Scientific Advisory Board Intellectual Property Financials

Oramed

An Oral Solution

Fate of proteins/peptides in GIT



Leads to protein breakdown and lack of absorption

oramed Pharmaceuticals Inc

Oramed POD™ Technology: The Solution



Enteric Coating

❖ pH sensitive - only degrades in the small intestine, thus protecting capsule constituents during travel through the upper gastrointestinal tract

Protease Inhibitors

- Protects protein from degradation by proteases once capsule degrades in the small intestine

Absorption Enhancers

- Assists with translocation of active ingredient (protein/ peptides) across intestinal membrane into bloodstream

Oramed's delivery platform **protects proteins** and **enhances their absorption**, allowing them to reach the bloodstream via the portal vein, thereby establishing a **more physiologic protein gradient when compared to other delivery systems.**

oramed Pharmaceuticals Inc

Oramed POD™ Technology

Versatile

Supports a wide range of protein sizes and doses



Simple

Simple blend of ingredients

Regulatory competence

No NCEs;
widely applied pharmacopoeia

Potential Oramed Technology Applications: Opportunities & Market

Insulin

$15+ billion 2012 global insulin market

$32 billion projected market for 2018

GLP-1 Analog

$2+ billion 2012 global GLP-1 market

Many patients stop treatment as a result of injection-related side effects

Other

Vaccines: **$24 billion** in 2013 - grew from $5 billion in 2000

Flu vaccine estimated at **$2.9 billion** in 2011 to $3.8 billion in 2018

Interferon: **$6.3 billion**, 2011 global market

oramed Pharmaceuticals Inc

Diabetes:

A Global Epidemic

Diabetes: A Global Epidemic





POPULATION

- **371 million**: Number of diabetics worldwide
  - 25.8 million in the US - projected to 44.1 million by 2034
- Type 2 diabetes accounts for about 90% of diabetes cases

COST

- $**471 billion**: estimated annual global economic burden - includes direct medical costs, disability, reduced productivity
- America: approx. $176 billion in direct medical costs and $69 billion in reduced productivity
- Projected American economic burden for direct medical costs **alone** by 2034 - **$336 billion** (based on current obesity levels, *Diabetes Care*, 2009).

Oramed Pipeline

ORMD-0801

Oral Insulin

ORMD-0801: Oral Insulin Administrations To-date



Total number of study subjects:

153

Total number of human doses:

1632

As of Nov 12, 2013

Portal insulin delivery is physiologic. Systemic insulin delivery is not.

- Blood glucose - insulin secretion system forms a 'closed-loop'
- Peripheral insulin promotes glucose uptake in fat and muscle
- First-pass hepatic metabolism extracts 80% of secreted insulin
- Systemic exposure is minimized



oramed Pharmaceuticals Inc

ORMD-0801

Type 2 Diabetes
(T2DM)

Type 2 Diabetes: Stages & Treatment Options



Initial Treatment:
- Lifestyle Modification
- Diet & Exercise

Single & Combination Oral Therapies:
- Reduce insulin resistance
- Stimulate insulin secretion

Final Treatment:
- Insulin Replacement (injections)

ORMD-0801 is *not* a substitute for insulin injections, but rather a new earlier treatment option

oramed Pharmaceuticals Inc.

Unique Initial Indication

Fasting Blood Glucose (FBG):

- Measurement of blood glucose levels after a fast (e.g. first thing in the morning)
- Effected by liver regulation of glucose and insulin levels in the body during a fast

Elevated FBG

- **Elevated FBG levels are a major issue in T2DM**
- **Main cause: excessive nocturnal glucose production from liver**
- Current treatments for correction of elevated FBG are suboptimal

FBG: Stats

- Approximately 70% of individuals with impaired FBG develop T2DM
- An estimated > 80% of T2DM patients exhibit abnormal FBG *and* fail to achieve glycemic control with Metformin or thiazolidinediones (TZDs) preparations

ORMD-0801: Unique Indication

- Nighttime dose
- Focused on reducing the excessive nocturnal glucose production from the liver

oramed Pharmaceuticals Inc

ORMD-0801: Preclinical - Dogs

n=4

8 mg insulin



- Healthy, non-diabetic, cannulated beagle dogs showed a 60-75% drop in blood glucose levels within 30-100 minutes of treatment
- No hypoglycemia or adverse events were observed over the three years of testing

ORMD-0801: Preclinical - Pigs

Fasting **3 mg insulin** **Pre-prandial**



NC; 4 independent test sessions
ORMD-0801; 10 independent sessions



NC; 6 independent test sessions
ORMD-0801; 5 independent sessions

No hypoglycemia or adverse events were observed

ORMD-0801 Trial Results: A Summary

Pre-clinical

- Healthy, non-diabetic, cannulated beagle dogs showed a 60-75% drop in blood glucose levels within 30-100 minutes of treatment
- No hypoglycemia or adverse events were observed over the three years of testing (in dogs)

T2DM Patients

ORA-D-004

- Randomized, double-blind, multi-center study on 29 patients - 21 dosed, 8 placebo, 6 weeks of monitoring
- Showed relevant clinical impact
- Good safety profile
- Safe and well tolerated by all patients
- No SAEs



ORMD-0801

Phase 2a Results

ORMD-0801: Phase 2a FDA Study

Overview:

•30 T2DM patients
•US site
•In-patient setting
•Double blind
•Randomized
•1 week of treatment

End Points:

•Primary end point:
- *Safety and tolerability*

•Secondary end points:
- *Pharmacodynamic effects on mean night time glucose*
- *Pharmacokinetics on AUC, Cmax, Tmax, T½*
- *Changes from baseline in FBG, morning fasting insulin, C-peptide*

Phase 2a Results: Safety

	Placebo (N=10)	ORMD-0801 460IU (N=10)	ORMD-0801 690IU (N=10)
Number of Subjects with At Least One Adverse Event	5 (50.0)	3 (30.0)	4 (40.0)
Ear and labyrinth disorders	1 (10.0)	0 (0.0)	0 (0.0)
Vertigo	1 (10.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	1 (10.0)	1 (10.0)	2 (20.0)
Constipation	0 (0.0)	0 (0.0)	2 (20.0)
Nausea	1 (10.0)	1 (10.0)	0 (0.0)
Infections and infestations	1 (10.0)	0 (0.0)	0 (0.0)
Urinary tract infection	1 (10.0)	0 (0.0)	0 (0.0)
Nervous system disorders	2 (20.0)	3 (30.0)	2 (20.0)
Headache	2 (20.0)	3 (30.0)	2 (20.0)
Skin and subcutaneous tissue disorders	1 (10.0)	0 (0.0)	0 (0.0)
Pruritus	1 (10.0)	0 (0.0)	0 (0.0)

No Serious Adverse Events

The study clearly shows that ORMD-0801 is safe and well tolerated

oramed Pharmaceuticals Inc

ORMD-0801

Type 1 Diabetes

(T1DM)

T1DM

- **T1DM is an autoimmune disease** – the body destroys its own insulin-producing cells leaving patients completely dependent on external insulin sources
- **5-10% of diabetes cases are T1DM** – approx. 18-37 million people worldwide.
- The disease was previously only seen in children, but **the majority of new-onset cases are seen in adults**; increasing at a rate of 3% per year

Treatment

- **T1DM is treated with 2 types of insulin** replacement therapy:
  - **long-acting insulin** (basal) to help maintain stable insulin levels during fast periods
  - **rapid-acting insulin** (bolus) prior to each meal
- Administration is via injection or pump

ORMD-0801 Oral Insulin and T1DM

- **Oramed is looking to replace the mealtime (bolus) insulin doses**, potentially reducing multiple daily injections
- **Mechanistic advantages**: Portal administration may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. Oral administration also offers the benefit of reduced systemic exposure and ease of use.

oramed Pharmaceuticals Inc

ORMD-0801: T1DM

Mean glucose n=8



Frequency glucose >200mg/dL



Results: Safe, well tolerated, reduced glycemia.

Design: 8 T1DM, monitor glycemic stability of orally administered ORMD-0801 (1 capsule (8 mg insulin) before meals, three times daily). Glucose monitored with continuous, blinded glucose monitor

ORMD-0901

Oral GLP-1 Analog (T2DM)

oramed
Pharmaceuticals Inc

Oral GLP-1 Analog (Exenatide)

GLP-1: Hormone Facts

- Secreted by the intestine
- Has effect on the satiety center in the brain
- Has effect on pancreatic β-cells

GLP-1 Analog: Drug Facts

- Good safety profile
- Mimics the natural hormone in the body
- Decreases blood glucose levels - aids in blood sugar balance
- **Does not cause hypoglycemia**
- Effectively reduces HbA1c
- Preserves beta cell function
- **Promotes weight loss**
- **Current therapy is via injection only**

ORMD-0901 Oral GLP-1

- Pre-IND package submitted to the US FDA Q3 2013
- IND enabling tox studies Q2, 2014
- P1b ex-US study Q2, 2014

oramed Pharmaceuticals Inc

Oral GLP-1 - ORMD-0901

Blunting of glucose excursions in dogs



Methods:

- Ø Healthy, fasting, cannulated dogs
- Ø Single dose ORMD-0901 formulation
- Ø Administered 30 minutes pre-glucose challenge
- Ø Blood samples collected every 15 minutes

Results: Subcutaneous exenatide delivery amounted to a 51% reduction in mean glucose $AUC_{0\text{-}150}$, while formulations AG4 and AG3 prompted 43% and 29% reductions, respectively (* p = 0.068, demonstrating a treatment-related trend for the sample size).

ORMD-0901 formulations preserved the biological activity of orally delivered exenatide. ORMD-0901 successfully curbed blood sugar excursions following glucose challenge.

oramed Pharmaceuticals Inc

ORMD-0901 - T2DM

Study

- First in Human
- 4 healthy volunteers
- Placebo controlled
- Pre-prandial

150 mg exenatide



Mean AUC

Placebo: 148.5±30.5

No Nausea

Insulin: 180.3±106.3

21%

Pipeline Overview

- ORMD-0801: Oral Insulin
- ORMD-0901: Oral Exenatide (GLP-1 Analog)
- Combination Therapy (ORMD-0801 + 0901)
- Platform POD™ Technology

Therapy	Indication	Phase I	Phase II	Phase III/ Market	Timeline
ORMD - 0801 Oral Insulin	T2DM				Q4, '13: Phase 2a completed Q2/3, '14: Phase 2b multi-center study projected initiation
	T1DM				Q1, '14: Phase 2a projected initiation Q1, '15: Phase 2b multi-center study projected initiation
ORMD-0901 Oral GLP-1	T2DM				Q2, '14: Preclinical/IND studies projected initiation Q2, '14: Phase 1b ex-US study projected initiation Q2, '15: Phase 2 multi-center study projected initiation

Corporate Overview

Management

Nadav Kidron, Esq, MBA
CEO & Director

Experience in various industries, including corporate law and technology

Miriam Kidron, PhD - CSO & Director

Senior Researcher at the Diabetes Unit of Hadassah Medical Center for more than 25 years

Josh Hexter - COO, VP Bus. Dev.

More than 15 years of prominent leadership roles in biotech and pharma

Yifat Zommer, CPA, MBA - CFO

Extensive experience in corporate financial management

Ehud Arbit, MD - Director of R&D

Former VP of Medical Research at Emisphere Technologies

Board of Directors

Michael Berelowitz, MD
- Chairman of Oramed SAB
- SVP Clinical Development & Medical Affairs, Pfizer (former)

Harold Jacob, MD
- Chief Medical Officer, Given Imaging (former)

Gerald Ostrov
- CEO, Bausch&Lomb (former)
- Senior level Executive J&J (former)

Leonard Sank
- Entrepreneur and businessman

Scientific Advisory Board

Michael Berelowitz, MD
Chairman of SAB

- Former SVP Clinical Development and Medical Affairs, Specialty Care Business at Pfizer Inc.
- Strong background in the Diabetes field.

Derek LeRoith, MD, PhD

- Professor of Medicine and Chief of Endocrinology, Diabetes and Bone Disease Unit, Mount Sinai School of Medicine, NY.

John Amatruda, MD

- Former SVP and Franchise Head of the Diabetes and Obesity Unit at Merck & Co.

Avram Herskho, MD, PhD –
Nobel Laureate, Chemistry, 2004

- Distinguished Professor in the Biochemistry Unit in the B. Rappaport Facility of Medicine, Technion, Haifa, Israel
- Nobel Laureate in Chemistry (2004)

Ele Ferrannini, MD, PhD

- Professor of Internal Medicine, University of Pisa School of Medicine. Professor of Medicine, Diabetes Unit Texas Health Science Center.
- Past President of the EASD.

Nir Barzilai, MD

- Director for the Institute of Aging Research. Member of Diabetes Research Center, Albert Einstein University College of Medicine.

oramed Pharmaceuticals Inc.

Intellectual Property: Five Primary Worldwide Patent Families

Methods and Compositions for Oral Administration of Proteins (Platform Technology)

- Expire 2026 & 2028
- Approved or Granted in Israel, Japan (both types), EU, Russia, China, Canada, Australia, New Zealand and South Africa
- Pending in multiple jurisdictions, including the US

Methods and Compositions for Oral Administration of Exenatide

- Expires 2028
- Approval or Granted in Australia, New Zealand and Israel
- Pending in multiple jurisdictions, including the US

Methods and Compositions (Insulin + Excenatide)

- Expires in 2032
- Pending status, including the US

Improved Protease Inhibitors

- Expires in 2032
- Pending status, including the US

oramed Pharmaceuticals Inc

Financial Overview*

Ticker: NASDAQ: ORMP

- $43M raised to date **
- No Debt
- Cash and investments: $23.8M
- Shares Issued: 9.7M
- Fully diluted: 11.9M ***



* As of January 14, 2014

** Including the shares of D.N.A Biomedical Solutions Ltd.

*** Including outstanding 0.9M options and 1.5M warrants

Anticipated Milestones 2014-2015

ORMD-0801
Oral Insulin

T2DM
- Completion of Phase 2a FDA study
- Initiation & Completion of Phase 2b multi-site study under US IND

T1DM
- Initiation & Completion of Phase 2a FDA study
- Initiation & Completion of Phase 2b multi-site study under US IND

ORMD-0901
Oral GLP-1Analog

- Initiation & Completion of IND-enabling studies
- Initiation & Completion of Phase 1b ex-US study
- Initiation of Phase 2 multi-site study under US IND

oramed
Pharmaceuticals Inc

Analyst Coverage

Oramed is followed by the analysts listed below:

Analyst	Firm
Raghuram Selvaraju	**Aegis Capital Corp.**
Graig Suvannavejh	**MLV & Co.**

Please note that any opinions, estimates or forecasts regarding Oramed's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oramed or its management. Oramed does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

In Summary

- Product pipeline with the potential to expand to other indications
- Proprietary technology platform (POD™) for oral delivery of peptides
- Clear proof of concept
- Strong IP
- Orally ingestible insulin capsule in Phase 2 clinical development under the US FDA
- Significant market opportunity
- World-leading scientific team
- Experienced management team

Breakthrough Technology for a Brighter Future



Contact :
Nadav Kidron
CEO
nadav@oramed.com

Josh Hexter
COO
josh@oramed.com

Exhibit 99.2

Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule

JERUSALEM February 10, 2014—Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes.

The protocol was submitted under Oramed's existing IND for ORMD-0801 to include both type 1 and type 2 diabetes indications. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients. This US- based study is expected to start later this quarter.

"With the encouraging data from our recent Phase 2a FDA trial on type 2 diabetic patients, we are moving forward on both the type 1 and type 2 indications by submitting this type 1 protocol to the FDA while gearing up for the Phase 2b multi-center trial on type 2 patients to take place later this year," commented Oramed CEO Nadav Kidron.

About ORMD-0801 Oral Insulin and T1DM

Oramed proposes to introduce ORMD-0801 to reduce the mealtime insulin doses, introducing a treatment regimen which would allow for fewer daily injections. Moreover, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. For more information on ORMD-0801, the content of which is not part of this press release, please visit http://oramed.com/index.php?page=14

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit www.oramed.com

Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman-Guiloff
Office: +972-2-566-0001
US: 1-718-831-2512
Email: aviva@oramed.com